Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cocrystal Pharma, Inc. on September 27, 2022. The report details a corporate action approved by stockholders at the 2022 Annual Meeting and finalized by the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a capital structure adjustment rather than financial performance results.
Material Changes
- Reverse Stock Split: The Company filed a Certificate of Amendment to effect a reverse stock split of all outstanding common stock at a ratio of one-for-12.
- Authorization: The split ratio was selected by the Board of Directors from a range of one-for-four through one-for-12 previously approved by stockholders.
- Effective Date: The amendment is scheduled to become effective on October 11, 2022, or a later date determined by the Nasdaq Stock Market.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, operational outlook, or specific risk factors beyond the standard incorporation by reference of the Amendment document. The primary purpose is to notify the market of the impending change in share count and price per share.
Investor Verification Checklist
- Verify the exact effective date of the reverse stock split with the Nasdaq Stock Market.
- Confirm the adjusted share count and corresponding price per share following the one-for-12 split.
- Review the full text of the Certificate of Amendment (Exhibit 3.1) for any additional terms or conditions.
- Check subsequent filings for any updates regarding the implementation of the split.